# Medicare's New GLP-1 Weight Loss Coverage: What Beneficiaries Should Know
Medicare launched a limited pilot program that covers GLP-1 receptor agonist medications, such as semaglutide and tirzepatide, specifically for weight loss in eligible beneficiaries. This marks a significant expansion since these drugs were previously covered only for diabetes and heart disease management.
The pilot program targets Medicare beneficiaries with obesity who meet specific criteria. Eligibility typically requires a body mass index of 30 or higher, or 27 or higher with weight-related health conditions like hypertension or sleep apnea. Beneficiaries must also work with a healthcare provider enrolled in the program and commit to behavioral modifications like diet and exercise changes.
Cost structure varies depending on a beneficiary's coverage plan. Those in traditional Medicare Part B may face standard coinsurance rates, while Medicare Advantage plans determine their own copays and deductibles. The federal government structured this as a pilot to gather data on real-world outcomes and costs before considering broader coverage expansion.
Semaglutide (known as Wegovy for weight loss) and tirzepatide (Zepbound) dominate the GLP-1 market. Both medications work by mimicking hormones that regulate appetite and blood sugar. Clinical trials demonstrate these drugs produce weight loss of 15 to 22 percent over 68 weeks when combined with lifestyle interventions.
Access remains limited. The pilot program covers only a subset of Medicare beneficiaries in participating regions. Supply chain constraints and manufacturing limitations continue affecting availability nationwide. Healthcare providers report high demand exceeding current supply.
Potential side effects include gastrointestinal issues, pancreatitis risk in susceptible patients, and thyroid concerns that require monitoring. Beneficiaries must undergo baseline health assessments before starting treatment and receive regular check